|
|
 |
|
Management Biographies |
|
|
 |
|
|
E. KEVIN MOORE
Vice President and Treasurer
Schering-Plough Corporation
Kenilworth, New Jersey
E. Kevin Moore is vice president and treasurer of Schering-Plough Corporation. He is responsible for management of Schering-Plough's financial assets, external financial relations and investments for employee benefit plans, as well as for the company's risk management and insurance functions.
Moore was elected to his present position effective January
1, 1996. He formerly had served as staff vice president and assistant
treasurer since joining Schering-Plough in 1993. Previously, he
was treasurer - Europe for the Dun and Bradstreet Corporation, London;
director - international finance for the Dun and Bradstreet Corporation,
New York City; and director - corporate finance for Pillsbury Company's
Burger King division, Miami, Fla.
Moore earned a bachelor of science degree in economics from
the University of North Carolina, Greensboro, and a master's degree
in international business from the University of South Carolina,
Columbia.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
